ENvue Medical, Inc. (FEED)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5M 3M 4.5M Q3 '15: 160K Q4 '15: 147K Q1 '16: 175K Q2 '16: 198K Q3 '16: 219K Q4 '16: 229K Q1 '17: 224K Q2 '17: 214K Q3 '17: 218K Q4 '17: 239K Q1 '18: 264K Q2 '18: 344K Q3 '18: 333K Q4 '18: 317K Q1 '19: 319K Q2 '19: 450K Q3 '19: 497K Q4 '19: 530K Q1 '20: 565K Q2 '20: 571K Q3 '20: 620K Q4 '20: 623K Q1 '21: 612K Q2 '21: 661K Q3 '21: 1M Q4 '21: 1.7M Q1 '22: 1.9M Q2 '22: 2M Q3 '22: 1.6M Q4 '23: 2.3M Q1 '24: 2.9M Q2 '24: 3.4M Q3 '24: 3.3M Q4 '24: 2.6M Q1 '25: 2.7M Q2 '25: 2.3M Q3 '25: 2.7M Q4 '25: 2.6M Q1 '26: 2.2M Q2 '26: 1.9M Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

-800K 0 800K 1.6M 2.4M Q4 '14: 30K Q1 '15: 89K Q2 '15: 74K Q3 '15: 114K Q4 '15: 98K Q1 '16: 109K Q2 '16: 125K Q3 '16: 129K Q4 '16: 142K Q1 '17: 148K Q2 '17: 142K Q3 '17: 151K Q4 '17: 151K Q1 '18: 170K Q2 '18: 213K Q3 '18: 178K Q4 '18: 159K Q1 '19: 157K Q2 '19: 287K Q3 '19: 326K Q4 '20: 214K Q1 '21: 240K Q2 '21: 410K Q3 '21: 539K Q4 '21: 770K Q1 '22: 799K Q2 '22: 872K Q3 '22: 724K Q4 '23: 1.5M Q1 '24: 2M Q2 '24: 2.2M Q3 '24: 2M Q4 '24: 1.5M Q1 '25: 1.2M Q2 '25: 750K Q3 '25: 806K Q4 '25: 153K Q1 '26: -271K Q2 '26: -502K Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '21 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q3 '16: -1.9M Q4 '16: -2.3M Q1 '17: -2.6M Q2 '17: -2.8M Q3 '17: -2.9M Q4 '17: -3.1M Q1 '18: -3.1M Q2 '18: -3.2M Q3 '18: -4M Q4 '18: -4.3M Q1 '19: -5.7M Q2 '19: -5.8M Q3 '19: -5.3M Q4 '19: -5.2M Q1 '20: -3.8M Q2 '20: -4.4M Q3 '20: -4.4M Q4 '20: -4.7M Q1 '21: -5.1M Q2 '21: -4.6M Q3 '21: -4.7M Q4 '21: -5.7M Q1 '22: -5.5M Q2 '22: -5.8M Q3 '22: -5.8M Q4 '22: -5M Q1 '23: -5M Q2 '23: -4.7M Q3 '23: -4.4M Q4 '23: -3.4M Q1 '24: -2.9M Q2 '24: -2.6M Q3 '24: -2.9M Q4 '24: -3.6M Q1 '25: -4.9M Q2 '25: -8.2M Q3 '25: -9.4M Q4 '25: -22.9M Q1 '26: -24.7M Q2 '26: -26.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-24M -16M -8M 0 8M 16M 24M Q3 '16: -2.5M Q4 '16: -2.8M Q1 '17: -3.2M Q2 '17: -3.5M Q3 '17: -4.4M Q4 '17: -5M Q1 '18: -4.9M Q2 '18: -4.9M Q3 '18: -4.6M Q4 '18: -4.2M Q1 '19: -6M Q2 '19: -6.3M Q3 '19: -5.8M Q4 '19: -5.8M Q1 '20: -4M Q2 '20: -4.4M Q3 '20: -4.5M Q4 '20: -4.3M Q1 '21: -8.3M Q2 '21: -7.1M Q3 '21: -12.8M Q4 '21: -14.3M Q1 '22: -10.5M Q2 '22: -11.6M Q3 '22: -5.9M Q4 '22: -5.4M Q1 '23: -5.4M Q2 '23: -5.2M Q3 '23: -5M Q4 '23: -3.7M Q1 '24: -3.2M Q2 '24: -2.8M Q3 '24: -3.1M Q4 '24: -3.7M Q1 '25: -5M Q2 '25: -8.3M Q3 '25: -6.8M Q4 '25: -18.2M Q1 '26: -20.1M Q2 '26: -21.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 900K 1.8M 2.7M Q3 '16: 90K Q4 '16: 87K Q1 '17: 76K Q2 '17: 72K Q3 '17: 67K Q4 '17: 88K Q1 '18: 94K Q2 '18: 131K Q3 '18: 155K Q4 '18: 158K Q1 '19: 162K Q2 '19: 163K Q3 '19: 171K Q4 '19: 249K Q1 '20: 286K Q2 '20: 461K Q3 '20: 458K Q4 '20: 409K Q1 '21: 372K Q2 '21: 251K Q3 '21: 471K Q4 '21: 925K Q1 '22: 1.1M Q2 '22: 1.2M Q3 '22: 905K Q4 '22: 585K Q1 '23: 538K Q2 '23: 412K Q3 '23: 504K Q4 '23: 746K Q1 '24: 884K Q2 '24: 1.2M Q3 '24: 1.3M Q4 '24: 1.1M Q1 '25: 1.4M Q2 '25: 1.6M Q3 '25: 1.9M Q4 '25: 2.4M Q1 '26: 2.5M Q2 '26: 2.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q3 '16: -1.5M Q4 '16: -1.5M Q1 '17: -1.6M Q2 '17: -1.6M Q3 '17: -1.8M Q4 '17: -2.2M Q1 '18: -2.6M Q2 '18: -3.1M Q3 '18: -3.4M Q4 '18: -3.5M Q1 '19: -3.6M Q2 '19: -3.4M Q3 '19: -3.7M Q4 '19: -3.9M Q1 '20: -3.8M Q2 '20: -3.5M Q3 '20: -3.1M Q4 '20: -3.4M Q1 '21: -3.5M Q2 '21: -4.9M Q3 '21: -4.8M Q4 '21: -4.4M Q1 '22: -5.2M Q2 '22: -5.2M Q3 '22: -6.6M Q4 '22: -7M Q1 '23: -6.5M Q2 '23: -5.7M Q3 '23: -4.4M Q4 '23: -3.6M Q1 '24: -3M Q2 '24: -2.3M Q3 '24: -2.5M Q4 '24: -2.5M Q1 '25: -3.3M Q2 '25: -6.1M Q3 '25: -7.2M Q4 '25: -9.4M Q1 '26: -12.3M Q2 '26: -11.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q2 '15: -1.4M Q3 '15: -1.3M Q4 '15: -1.5M Q1 '16: -1.6M Q2 '16: -1.5M Q3 '16: -1.5M Q4 '16: -1.5M Q1 '17: -1.6M Q2 '17: -1.6M Q3 '17: -1.8M Q4 '18: -3.6M Q4 '21: -4.4M Q4 '23: -3.6M Q1 '24: -3M Q2 '24: -2.3M Q3 '24: -2.5M Q4 '24: -2.5M Q1 '25: -3.3M Q2 '25: -6.1M Q3 '25: -7.3M Q4 '25: -9.4M Q1 '26: -12.4M Q2 '26: -11.7M Q3 '15 Q2 '16 Q1 '17 Q4 '18 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q1 '21: 24.2M Q2 '21: 24.8M Q3 '21: 26.1M Q1 '22: 1.4M Q2 '22: 1.4M Q3 '22: 1.4M Q1 '23: 1.7M Q2 '23: 1.7M Q3 '23: 1.7M Q1 '24: 247K Q2 '24: 25.3K Q3 '24: 280.3K Q1 '25: 62.6K Q2 '25: 484.6K Q3 '25: 858.4K Q1 '26: 3.3M Q2 '26: 6.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-210.00 -140.00 -70.00 0.00 70.00 140.00 210.00 Q2 '15: -11.05 Q3 '15: -6.34 Q4 '15: -1.34 Q1 '16: -0.60 Q2 '16: -0.63 Q3 '16: -0.53 Q4 '16: -0.62 Q1 '17: -0.88 Q2 '17: -0.93 Q3 '17: -1.15 Q4 '17: -1.16 Q1 '18: -0.91 Q2 '18: -0.86 Q3 '18: -0.72 Q4 '18: -0.64 Q1 '19: -0.92 Q2 '19: -0.95 Q3 '19: -0.86 Q4 '19: -0.85 Q1 '20: -0.58 Q2 '20: -0.62 Q3 '20: -0.60 Q4 '20: -0.42 Q1 '21: -0.49 Q2 '21: -0.30 Q3 '21: -0.46 Q4 '21: -0.57 Q1 '22: -1.18 Q2 '22: -2.10 Q3 '22: -2.52 Q4 '22: -3.84 Q1 '23: -3.70 Q2 '23: -3.42 Q3 '23: -3.16 Q4 '23: -23.33 Q1 '24: -20.28 Q2 '24: -46.81 Q3 '24: -49.95 Q4 '24: -157.28 Q1 '25: -189.56 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.